Serum Procalcitonin and Presepsin Levels in Patients with Generalized Pustular Psoriasis

Table 2

Characteristics of the study patients with generalized pustular psoriasis (GPP), showing the serum inflammatory marker levels before and after treatment in 15 patients.

Age (years)	Sex	PCT (ng/mL)		P-SEP (pg/mL)		CRP (mg/dL)		Treatment
		Baseline	Follow-up	Baseline	Follow-up	Baseline	Follow-up
76	M	0.07	<0.02	581	269	6.2	0.7	Etretinate
73	M	5.58	0.07	7190	807	23.7	4.5	LCAP
55	M	1.09	<0.02	1220	291	7.7	0.1	MTX+CyA
70	M	0.03	<0.02	538	267	4.7	0.1	Etretinate+PSL
62	F	0.45	0.03	609	120	26.2	0.3	MTX
71	M	0.06	0.03	526	209	4.4	1.2	PSL
67	M	0.07	0.04	757	210	14.5	0.2	IFX
54	F	0.35	<0.02	301	125	22.2	0.2	IFX
55	M	0.18	0.06	1200	834	5.8	1.7	MTX+CyA
57	M	<0.02	<0.02	195	116	1	0.1	GMA
62	M	0.25	0.08	1160	631	10.3	0.2	CyA
92	M	0.28	0.04	173	223	0.1	0.2	GMA
78	F	0.07	0.03	450	308	1.5	0.5	GMA
52	F	0.04	0.03	146	162	3.9	0.1	PSL
36	F	0.08	0.03	434	192	8.15	0.15	SEC

PCT: procalcitonin; P-SEP: presepsin; CRP: C-reactive protein; LCAP: leukocytapheresis; MTX: methotrexate; CyA: cyclosporine; PSL: prednisolone; IFX: infliximab; GMA: granulocyte and monocyte apheresis; SEC: secukinumab.